He said that the Sinopharm vaccine was developed by Sinopharm’s Beijing Institute of Biological Products.
READ ALSO: Banks give customers ultimatum to return unutilised Forex within two weeks
The NPHCDA boss noted that the vaccine has completed three trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru and the United Arab Emirates with over 60,000 participants.
He said the BBIBP-CorV shares similar technology with CoronaVac, Covaxin, and other inactivated virus vaccines for COVID-19.
Dr Faisal also said that NAFDAC recently gave the nod for its use in Nigeria although the vaccine had received the World Health Organisation certification.
“NAFDAC has approved the Sinopharm vaccine, the approval was given three days ago; and yes, the Sinopharm vaccine has also received WHO certification,” he said.
We do everything possible to supply quality news and information to all our valuable readers day in, day out and we are committed to keep doing this.
Your kind donation will help our continuous research efforts.




















